What are the side effects of Ripretinib?

The most common adverse reactions of Ripretinib (≥20%) are alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythema paresthesia syndrome (PPFS) and vomiting. The most common grade 3 or 4 laboratory abnormalities (≥4%) were elevated lipase and decreased phosphate. Clinically relevant adverse reactions occurring in <10% of patients include cardiac ischemic events (including acute coronary syndrome and fatal cardiac arrest or myocardial infarction), photosensitivity.

Serious adverse reactions, including abdominal pain, anemia, nausea and vomiting, occurred in 31% of patients treated with repetinib. Seven percent of patients required dose reduction due to adverse reactions, including abdominal pain, agitation, alopecia, arthritis, dermatology, gastrointestinal disorders, hyperesthesia, myalgia, PPES, and weight loss. Twenty-four percent of patients experienced dose interruptions due to adverse reactions, including nausea, elevated blood bilirubin, and PPES. Eight percent of patients permanently discontinued treatment due to adverse reactions, including worsening of systemic health, anemia, heart failure, PPES, and vomiting.

The original drug of Ripetinib has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.